Drug maker Novartis released highly anticipated results from its clinical trial, PARADIGM-HF, showing its new heart failure drug cut cardiovascular deaths by 20%. The results were announced at the European Society of Cardiology meeting on Saturday. Novartis has been testing a drug called LCZ696 for chronic heart failure in hopes of replacing ACE inhibitors, one of the mainstays of heart failure treatment.